Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes

Vamsi Kota; Augustina Ogbonnaya; Eileen Farrelly; Bridgette Kanz Schroader; Aditya Raju; Fjoralba Kristo; Mehul Dalal

doi:10.2217/fon-2022-0334

Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes

Vamsi Kota, Augustina Ogbonnaya, Eileen Farrelly, Bridgette Kanz Schroader, Aditya Raju, Fjoralba Kristo, Mehul Dalal

Pulmonary Disease

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark analysis and the results were validated using a time-varying analysis. Results: The rate of AML transformation was 26.9% at 1 year. Patients who transformed to AML had a higher risk of death than patients who did not in the 6-month landmark analysis (HR: 1.82; p: 0.0072) and time-varying analysis at 1 year (HR: 2.85; p < 0.0001). Patients treated with azacitidine and decitabine in first-line therapy had similar results. Conclusion: HR-MDS transformation to AML is associated with inferior OS in patients with HR-MDS initiating first-line therapy.

Original language	English (US)
Pages (from-to)	4017-4029
Number of pages	13
Journal	Future Oncology
Volume	18
Issue number	36
DOIs	https://doi.org/10.2217/fon-2022-0334
State	Published - Nov 1 2022

Keywords

AML
MDS
higher-risk
overall survival
transformation

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2022-0334

Cite this

@article{0114d6af35c34648a0c7189eb0a8aa96,

title = "Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes",

abstract = "Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark analysis and the results were validated using a time-varying analysis. Results: The rate of AML transformation was 26.9% at 1 year. Patients who transformed to AML had a higher risk of death than patients who did not in the 6-month landmark analysis (HR: 1.82; p: 0.0072) and time-varying analysis at 1 year (HR: 2.85; p < 0.0001). Patients treated with azacitidine and decitabine in first-line therapy had similar results. Conclusion: HR-MDS transformation to AML is associated with inferior OS in patients with HR-MDS initiating first-line therapy.",

keywords = "AML, MDS, higher-risk, overall survival, transformation",

author = "Vamsi Kota and Augustina Ogbonnaya and Eileen Farrelly and Schroader, {Bridgette Kanz} and Aditya Raju and Fjoralba Kristo and Mehul Dalal",

note = "Funding Information: V Kota is a consultant for Takeda Development Center Americas, Inc. M Dalal and F Kristo are employees of Takeda Development Center Americas, Inc. A Ogbonnaya, E Farrelly, BK Schroader and A Raju are employees of Xcenda, LLC, and Xcenda, LLC received funding to conduct this study. We would like to acknowledge K Hennenfent and S Castelo for their medical writing support, as well as CB Schnell for her editorial assistance. All support was funded by Takeda Development Center Americas, Inc. (TDCA), MA, USA. This study was funded by Takeda Development Center Americas, Inc. (TDCA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Ethical conduct of research Publisher Copyright: {\textcopyright} 2023 Takeda.",

year = "2022",

month = nov,

day = "1",

doi = "10.2217/fon-2022-0334",

language = "English (US)",

volume = "18",

pages = "4017--4029",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "36",

}

TY - JOUR

T1 - Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes

AU - Kota, Vamsi

AU - Ogbonnaya, Augustina

AU - Farrelly, Eileen

AU - Schroader, Bridgette Kanz

AU - Raju, Aditya

AU - Kristo, Fjoralba

AU - Dalal, Mehul

N1 - Funding Information: V Kota is a consultant for Takeda Development Center Americas, Inc. M Dalal and F Kristo are employees of Takeda Development Center Americas, Inc. A Ogbonnaya, E Farrelly, BK Schroader and A Raju are employees of Xcenda, LLC, and Xcenda, LLC received funding to conduct this study. We would like to acknowledge K Hennenfent and S Castelo for their medical writing support, as well as CB Schnell for her editorial assistance. All support was funded by Takeda Development Center Americas, Inc. (TDCA), MA, USA. This study was funded by Takeda Development Center Americas, Inc. (TDCA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Ethical conduct of research Publisher Copyright: © 2023 Takeda.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark analysis and the results were validated using a time-varying analysis. Results: The rate of AML transformation was 26.9% at 1 year. Patients who transformed to AML had a higher risk of death than patients who did not in the 6-month landmark analysis (HR: 1.82; p: 0.0072) and time-varying analysis at 1 year (HR: 2.85; p < 0.0001). Patients treated with azacitidine and decitabine in first-line therapy had similar results. Conclusion: HR-MDS transformation to AML is associated with inferior OS in patients with HR-MDS initiating first-line therapy.

AB - Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark analysis and the results were validated using a time-varying analysis. Results: The rate of AML transformation was 26.9% at 1 year. Patients who transformed to AML had a higher risk of death than patients who did not in the 6-month landmark analysis (HR: 1.82; p: 0.0072) and time-varying analysis at 1 year (HR: 2.85; p < 0.0001). Patients treated with azacitidine and decitabine in first-line therapy had similar results. Conclusion: HR-MDS transformation to AML is associated with inferior OS in patients with HR-MDS initiating first-line therapy.

KW - AML

KW - MDS

KW - higher-risk

KW - overall survival

KW - transformation

UR - http://www.scopus.com/inward/record.url?scp=85148114390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148114390&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0334

DO - 10.2217/fon-2022-0334

M3 - Article

C2 - 36622291

AN - SCOPUS:85148114390

SN - 1479-6694

VL - 18

SP - 4017

EP - 4029

JO - Future Oncology

JF - Future Oncology

IS - 36

ER -

Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this